Trial Profile
An open-label, multi-center, non-randomized Phase Ib study to investigate safety andtolerability of radium Ra 223 dichloride (BAY 88-8223) administered in combination with paclitaxel in cancer subjects with bone lesions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary) ; Paclitaxel
- Indications Bone metastases; Cancer
- Focus Adverse reactions
- Sponsors Bayer HealthCare
- 12 May 2016 Status changed from recruiting to completed.
- 22 Dec 2015 New trial record